Preloader image
page-template-default,page,page-id-1567,passage-core-1.0.2,passage-theme-ver-2.0.2,ajax_updown_fade,page_not_loaded,large,shadow3,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

About COPE

The Coalition on Physician Education in Substance Use Disorders (COPE) is a voluntary organization devoted to improving patient care and the public health by assuring that all physicians are trained to prevent, identify, and provide specialty-appropriate interventions for patients with substance use problems.

Executive Director

Jenifer Van Deusen:
COPE Executive Director Jenifer Van Deusen holds a B.S. in Education from Lesley University and an M.Ed. in Educational Administration from the University of Southern Maine, with extensive additional academic work in medical education, educational leadership, organizational development and systems thinking. Jen currently serves as University of New England College of Osteopathic Medicine’s (UNE COM) Interprofessional Education and Practice Faculty and as a member of UNE COM’s substance use curriculum team. Her long career includes service as a public school teacher, a consultant with Maine’s Department of Education, the leader of a statewide network of teachers teaching teachers, curriculum director in a school district, the education specialist in a family medicine residency, and as UNE COM’s Director of Curriculum. Jen’s interests include successful curriculum transformation, technological solutions that support high-quality learning, teaching and assessment, faculty development, and grant writing. Outside of work, you can find Jen out in nature, learning to play the dulcimer and exploring inner and outer frontiers.


David Lewis

David C. Lewis, M.D.:
David C. Lewis, M.D., is a Professor Emeritus of Community Health and Medicine and the Donald G. Millar Distinguished Professor Emeritus of Alcohol and Addiction Studies at Brown University. In 1982, he founded, and for eighteen years directed, the Brown University Center for Alcohol and Addiction Studies. Dr. Lewis is a graduate of Brown University and Harvard Medical School. Trained in Internal Medicine, Dr. Lewis is a member of several Boards of Directors, including the National Council on Alcoholism and Drug Dependence (where he was Chairman of the Board), the American Society of Addiction Medicine, the Drug Policy Alliance, the Association for Medical Education and Research in Substance Abuse and the Veterans Healing Initiative. He is the founder of Physician Leadership on National Drug Policy and now on the Board of Directors of the new PLNDP: Physicians and Lawyers for National Drug Policy. Dr. Lewis was a member of the Institute of Medicine –National Academy of Sciences Committee that conducted a two year study under the sponsorship of Congress and the Department of Defense entitled “Substance Use Disorders in the US Armed Forces.” Their recently issued report labeled the prevention and treatment programs for alcohol and other drug problems a public health crisis. The author of over 400 publications, Dr. Lewis has an international reputation for his work on substance abuse treatment, medical education and public policy.

Stephen Wyatt, D.O.

Vice President
Stephen Wyatt, D.O.:
Stephen Wyatt, D.O., currently serves as the Medical Director of Addiction Medicine at Atrium Health, Charlotte, NC. He is a CHS Professor of Psychiatry and an adjunct clinical faculty member of the University of North Carolina. He is the Chairman of the NC Psychiatric Asso., Addiction Psychiatry Committee, Past President of the American Osteopathic Academy of Addiction Medicine, and recent recipient of the Governors Institute’s, Dr. Frederick B. Glaser Award. He is a Co-PI for the SAMHSA supported Provider Clinical Support System and Co-Chair of the ASAM Clinical Guidelines for Office Based Opioid Treatment Development Committee.

Mark L. Kraus, MD

Mark L. Kraus, M.D.:
Mark L. Kraus, MD, FASAM, DABAM is a General Internist at Franklin Medical Group/Trinity Healthcare of New England in Waterbury, Connecticut, Past Vice President and a Board Member of the American Society of Addiction Medicine (ASAM), a Distinguished Fellow of ASAM and a Diplomate of the American Board of Addiction Medicine. Dr. Kraus is an Assistant Clinical Professor of Medicine at Yale University School of Medicine, does clinical research in and teaches Addiction Medicine and General Internal Medicine to Yale and St. Mary’s Hospital Primary Care General Internal Medicine Residents. Dr. Kraus has written numerous articles and chapters about Addiction and has lectured nationally and internationally on the subject.

In addition to being a former Vice-President of ASAM, Dr. Kraus was a member of ASAM’s Legislative and Finance Committee, Co-Chair of the Patient Advocacy Task Force and Chairman of ASAM’s Consensus 42-CFR Action group (AAAP, AOA-AM, AMERSA), Chairman of ASAM’s Development Committee for Strategic Planning and former Co-Chair of and current member of ASAM’s Public Policy Committee. Dr. Kraus is a member of the steering committee of the Coalition of Physician Education in Substance Use Disorders (COPE) and current Treasurer and Board Member of COPE. Dr. Kraus was Co-Chair of the Physician’s Task Force on Education for AMERSA.

Dr. Kraus has been a member of the Primary Care Physician’s Work Group for NIDA, the Expert Panel of the White House Office of National Drug Control Policy for the Addiction Medicine Education Summit meetings, the Connecticut Alcohol and Drug Policy Council and the Connecticut Mental Health Policy Council. He serves as a Mentor in the Physician Clinical Support System for Buprenorphine, Methadone and Medical Assisted Treatment for Opiate Dependence.

Dr. Kraus is a founder and past President of ASAM’s Connecticut Chapter, the former Director of Addiction Medicine at two Hospitals in Waterbury, Connecticut. He is currently Chairman of the Connecticut State Medical Society’s Addiction Medicine Committee and Chief Medical Officer of Connecticut Counseling Centers, Inc.

J. Harry (Bud) Isaacson

J. Harry (Bud) Isaacson:
J. Harry (Bud) Isaacson, MD, FACP is the Executive Dean of the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He received his medical degree from the University of Michigan in 1984 and completed his Internal Medicine Residency and Chief Residency at the University of Vermont in 1988. Dr. Isaacson joined the Department of General Internal Medicine at the Cleveland Clinic in 1993 where he practices and teaches. He served as the Assistant Dean for Clinical Education at CCLCM prior to being selected as Executive Dean. He has served as Chair of the Professionalism Council and has served as a member of the Board of Governors at Cleveland Clinic. Professionalism Council initiatives have included development of a 6 session on-boarding program focusing on professionalism, revision of the annual professionalism review process and creation of an interactive course – Civility, Professionalism and Resilience (CPR) for leaders and staff at the Cleveland Clinic. Dr. Isaacson’s interests beyond clinical medicine include medical education, professionalism, doctor/patient communication skills, substance use disorders and the use of appreciative inquiry in medicine. He is a Fellow of the American College of Physicians and a member of the Society of General Internal Medicine.

John Renner

John A. Renner, Jr., M.D.:
Dr. Renner is Professor of Psychiatry, Boston University School of Medicine and Associate Chief of Psychiatry, VA Boston Healthcare System. He is past President of the American Academy of Addiction Psychiatry, former Chair of the American Psychiatric Association Council on Addiction Psychiatry, and Director of the Boston University/VA Addiction Psychiatry Residency. Dr. Renner has developed nationally recognized models for training physicians in addiction treatment, has written extensively on the treatment of alcoholism and drug addiction and has played a major role nationally training physicians in the use of buprenorphine. He is senior editor of the American Psychiatric Association Publishing’s Handbook on Office-Based Buprenorphine Treatment of Opioid Use Disorder.